Solazyme, Inc. (NASDAQ: SZYM) is surging on news this morning that the renewable oil and bioproducts outfit has formed a joint venture with a unit of Bunge Limited (NYSE: BG) to build, own and operate a commercial-scale renewable tailored oils production facility adjacent to Bunge’s Moema sugarcane mill in Brazil.
The venture will operate under the name Solazyme Bunge Produtos Renováveis Ltda. and is expected to have an annual production capacity of 100,000 metric tons of oil. The facility will utilize Solazyme’s renewable tailored oil production technology and will also utilize Bunge’s sugarcane supply and processing capabilities. The move will allow the production of sustainable tailored triglyceride oils for use in oleochemical and fuel applications in the Brazilian domestic market.
While the exact financial terms of the agreement were not disclosed, it is being treated as a win for Solazyme with a 7.6% gain to $15.40 in the pre-market trading. Solazyme has a market value of $863 million and this company just came public last summer.
JON C. OGG
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
